BIOS Capital Management, LP reported 5 positions worth $41.56M for the quarter ended Jun 30, 2026, down 21.0% on the prior quarter. It opened 0 new positions, added to 1, trimmed 1 and exited 0. Its largest holding is Actuate Therapeutics, Inc. at 37% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| RNTX Rein Therapeutics, Inc. | +1.00M | +50.4% | $1.04M | 7.46% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| LTRN Lantern Pharma Inc. | -615.0K | -71.1% | $2.56M | 2.5% |
No new positions this quarter.
No positions were closed this quarter.
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | ACTU Actuate Therapeutics, Inc. | Healthcare | 10.05M | $15.38M | 37% | 0 | 0.0% | Unchanged | 41.85% |
| 2 | IRD Opus Genetics, Inc. | Healthcare | 3.68M | $15.14M | 36.43% | 0 | 0.0% | Unchanged | 3.86% |
| 3 | CGTX Cognition Therapeutics Inc | Healthcare | 6.00M | $6.90M | 16.6% | 0 | 0.0% | Unchanged | 6.31% |
| 4 | RNTX Rein Therapeutics, Inc. | Healthcare | 2.98M | $3.10M | 7.46% | +1.00M | +50.4% | Added | 3.48% |
| 5 | LTRN Lantern Pharma Inc. | Healthcare | 249.4K | $1.04M | 2.5% | -615.0K | -71.1% | Reduced | 1.95% |
Tip. Select a row to see that position’s full history at BIOS Capital Management.
As of its Q2 2026 13F filing, BIOS Capital Management, LP’s five largest positions were Actuate Therapeutics, Inc. (ACTU) at 37.0%, Opus Genetics, Inc. (IRD) at 36.4%, Cognition Therapeutics Inc (CGTX) at 16.6%, Rein Therapeutics, Inc. (RNTX) at 7.5%, Lantern Pharma Inc. (LTRN) at 2.5% of the reported portfolio.
BIOS Capital Management, LP reported a 13F portfolio worth $41.56M across 5 positions for Q2 2026. That is down 21.0% from the previous quarter.
Its largest purchases by value were Rein Therapeutics, Inc. ($1.04M). It opened 0 new positions.
Its largest sales by value were Lantern Pharma Inc. ($2.56M). It exited 0 positions entirely.
From the Form 13F-HR reports BIOS Capital Management, LP files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.